Whole Live Micro-organism, Cell, Or Virus Containing Patents (Class 424/93.1)
  • Patent number: 10392632
    Abstract: This application relates to the fields of gene therapy and molecular biology. In accordance with the present invention, an adeno-associated virus (AAV) vector comprising an altered capsid protein is provided. More specifically, this invention provides adeno-associated viral vectors comprising protein capsid variants which accelerate vector breakdown and clearance, thereby reducing undesirable immune responses.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: August 27, 2019
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: John Fraser Wright, Olga Zelenaia, Bernd Hauck, Federico Mingozzi, Katherine A. High
  • Patent number: 10369254
    Abstract: The invention provides for a device, system, and methods for using the same with kidney progenitor cells, specifically ureteric bud (UB) cells, metanephric mesenchymal (MM) cells, and the stromal cell (SC) subpopulation of the metanephric mesenchyme, to generate an embryonic kidney organoid that can be implanted into a mammalian subject to create a living, functional kidney.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 6, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, U.S. DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Norimoto Yanagawa, Masaki Nishikawa, Morgan Hamon, Peter Viktor Hauser
  • Patent number: 10344073
    Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 9, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Abraham Rutenberg, Ronny Uzana, Michal Lotem, Arthur Machlenkin, Galit Eisenberg, Tamar Peretz-Yablonsky, Shoshana Frankenburg, Roni Engelstein
  • Patent number: 10332286
    Abstract: Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 25, 2019
    Assignee: DexCom, Inc.
    Inventors: Georgios Zamanakos, Daniel Justin Wiedeback, Jeffrey Grant Stewart, Eli Reihman, David Price, Lauren C. Miller, Keri Leone, Dan Kraemer, Katherine Eng Kirby, Greg Kida, Apurv Ullas Kamath, Adam R. Greene, Rebecca Gimenez, Sarah Paige Elli, Rian Draeger, Shane Philip Delmore, Leif N. Bowman
  • Patent number: 10287641
    Abstract: The invention relates to new isolated Lactobacillus strains chosen from Lactobacillus mellifer Bin4N.sup.T (LMG P-28344) and Lactobacillus apinorum Fhon13N.sup.T (LMG P-28345), which have been isolated from honeybees or their processed food. The bacterial strains have unique properties such as production of benzene, free fatty acids and 2-heptanone, rendering them useful in many areas such as in food and beverage products, feed products and medical products.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 14, 2019
    Assignee: CONCELLAE AB
    Inventors: Tobias Olofsson, Alejandra Vasquez
  • Patent number: 10286009
    Abstract: The present disclosure provides methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: May 14, 2019
    Assignee: Asterias Biotherapeutics, Inc.
    Inventors: Edward D. Wirth, III, Jane S. Lebkowski
  • Patent number: 10272102
    Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: April 30, 2019
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Martin Westphal, Silke Baasner
  • Patent number: 10232000
    Abstract: The present disclosure relates to stem cells derived from the basal portion of the chorionic trophoblast layer (bCT), which is a part of the issues of the placenta, and cell therapy comprising same. Stem cells derived from the basal portion of the chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristic as compared with the conventional stem cells derived from the full placenta or other tissues, and exhibit excellent tissue regeneration effect in an animal model, thus can be effectively used in cell therapy.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: March 19, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10227567
    Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: March 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
  • Patent number: 10214751
    Abstract: The present invention provides a method for treatment of biomass material by fermentation, said method comprises a pre-treatment of the biomass material by thermal hydrolysis and wet explosion, resulting in an intermediate product having a dry matter concentration above 25% and temperature above 90° C. which is to be introduced to the fermentation, wherein a part of the content of the digestion tank used for the fermentation is recirculated and mixed with a part of the intermediate product from the pre-treatment.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 26, 2019
    Assignee: CAMBI TECHNOLOGY AS
    Inventors: Paal Jahre Nilsen, Hans Rasmus Holte
  • Patent number: 10189955
    Abstract: A nested capsule having a first capsule held within a second capsule. Each of the first and second capsules has a shell that is a supramolecular cross-linked network, such as a cucurbituril supramolecular cross-linked network. Each capsule shell is obtained or is obtainable from the complexation of a composition including a host, such as cucurbituril, and one or more building blocks having suitable guest functionality for the host, thereby to form a supramolecular cross-linked network. The nested capsules are suitable for delivering and selectively releasing an encapsulant at a location.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 29, 2019
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Jing Zhang, Roger Coulston, Richard Parker, Christopher Abell, Oren Scherman, Ziyi Yu
  • Patent number: 10179918
    Abstract: Methods and compositions for increasing transgene expression and/or activity, including for increasing nuclease-mediated genomic modifications.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 15, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Gregory J. Cost
  • Patent number: 10166261
    Abstract: The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 1, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • Patent number: 10160955
    Abstract: A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 25, 2018
    Assignee: Board of Supervisors of Louisiana State University
    Inventor: Yuping Wang
  • Patent number: 10123517
    Abstract: Immunocompetent animal models having immunological tolerance to a xenograft and methods of producing the same. The animal models are tolerized to the xenograft in the pre-immune, fetal or embryonic stage, followed by transplanting the xenograft into the animal in the post-natal stage, such that the post-natal animal is immunologically tolerant to the xenograft, while remaining immunocompetent.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 13, 2018
    Assignee: Kansas State University Research Foundation
    Inventors: Deryl Troyer, Duane Davis, Stefan Bossmann
  • Patent number: 10119123
    Abstract: The present invention relates to the reprogramming of differentiated somatic cells, such as those differentiated cells that arise from embryonic mesoderm, into glial cells. Glial cells produced from this reprogramming are functionally equivalent to glial cells that arise from ectodermal origins.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: November 6, 2018
    Assignee: Case Western Reserve University
    Inventors: Paul J. Tesar, Robert H. Miller, Fadi J. Najm
  • Patent number: 10114008
    Abstract: Disclosed are methods and systems for testing the effects of various morphogens and/or feeder cells on the differentiation of pluripotent cells. The assays described herein can be used for determining the optimum conditions that lead to differentiation of stem cells. Once the optimum conditions for stem cell differentiation are determined, such cells may be used in a variety of therapies.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: October 30, 2018
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Yansong Gu
  • Patent number: 10111821
    Abstract: Methods are disclosed for administering electromagnetic radiation (EMR), which may include filtering EMR from part of the EMR spectrum while allowing passage of EMR at a desired wavelength range. Uses may include the treatment of such conditions as psoriasis, vitiligo, pruritus, acne, vitamin-D deficiency and atopic dermatitis. Topical creams, sprays, or other compositions may be used, with or without dosimeters, or in conjunction with an application, which calculates local UV exposure and other factors relating to dosage.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: October 30, 2018
    Assignee: Applied Biology, Inc.
    Inventors: Andy Ofer Goren, John McCoy
  • Patent number: 10098847
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 16, 2018
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 10077426
    Abstract: The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: September 18, 2018
    Assignee: Enlivex Therapeutics Ltd
    Inventors: Dror Mevorach, Inna Reiner
  • Patent number: 10071149
    Abstract: The present invention is related to various vaccine compositions against Bordetella avium and methods for preparing and administering the various vaccine compositions. The present invention is related to multivalent vaccines compositions such as bivalent or trivalent vaccines for inoculating turkeys against from Bordetella avium rhinotracheitis or coryza due to Bordetella avium infection as well as methods of preparing and administering the multivalent vaccine compositions.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: September 11, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Marcus M. Jensen, Richard A. Robison
  • Patent number: 10066215
    Abstract: Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: September 4, 2018
    Assignee: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Kyuhyun Lee, Seongtae Yun, Daekyung Koh, Hong-Kyu Lee, Eui-Cheol Jo
  • Patent number: 10064931
    Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 4, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew P. Morrow
  • Patent number: 10059923
    Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: August 28, 2018
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Johannes L. Zakrzewski, Marcel R. M. Van Den Brink, Michel Sadelain
  • Patent number: 10052353
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: August 21, 2018
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institute
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Patent number: 10052372
    Abstract: A method of treating a cancer in a subject is disclosed, comprising: (1) isolating T cells from a subject; generating or expanding a population of T cells specific for a virus by a method comprising: stimulating T cells by culture in the presence of antigen presenting cells (APCs) presenting a peptide of the virus, wherein 10 to 25% of the media in which the cells are cultured is conditioned media obtained from a stimulation culture comprising T cells and APCs presenting a peptide of the virus; and (3) administering the generated or expanded population of T cells to a subject. Also disclosed are methods for generating or expanding a population of T cells specific for a virus.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 21, 2018
    Assignee: TESSA THERAPEUTICS PTE LTD
    Inventors: Peter Wang, Chunxiao Wu
  • Patent number: 10039819
    Abstract: The present invention provides attenuated M haemolitica strains that elicit an immune response in animal against M haemolitica, compositions comprising said strains, methods of vaccination against M haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 7, 2018
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Biotechnology Research and Development Corporation
    Inventors: Robert E. Briggs, Fred M. Tatum
  • Patent number: 10016371
    Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: July 10, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventors: Benjamin George Keselowsky, Jamal Lewis, Abhinav Acharya, Michael J. Clare-Salzler
  • Patent number: 9987296
    Abstract: Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 5, 2018
    Inventor: Lanny Johnson
  • Patent number: 9987312
    Abstract: To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus Bacillus, Oceanobacillus, Paenibacillus, Anoxybacillus, Lysinibacillus, Methanopyrus, Geogemma, Pyrolobus, Pyrodictium, Hyperthermus, Pyrococcus, Pyrobaculum, Thermococcus, Aeropyrum, Aquifex, Thermotoga, Thermodesulfobacterium, Thermus, Geobacillus, and Thermomyces.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 5, 2018
    Assignees: JAPAN ECO-SCIENCE CO., LTD., NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY, INDEPENDENT ADMINISTRATIVE INSTITUTION NATIONAL FISHERIES UNIVERSITY, MIROKU CO., LTD., KEIYO PLANT ENGINEERING CO., LTD.
    Inventors: Hirokuni Miyamoto, Hiroaki Kodama, Takumi Nishiuchi, Teruo Matsushita, Hisashi Miyamoto, Sankichi Horiuchi, Manami Seta, Kenichi Mori, Masahira Hattori, Kazuo Ogawa
  • Patent number: 9974817
    Abstract: The invention provides a composition comprising Lactobacillus fermentum ME-3 strain DSM 14241 for use in preventing, alleviating the symptoms of or treating, alone or as an adjuvant component, a metabolic syndrome related disorder selected from prediabetes, type 2 diabetes and cardiovascular disease. The effect may be achieved by simultaneously: decreasing the level of glycated haemoglobin HbA1c, decreasing or preventing low-grade inflammation on a cellular level and increasing the level of adiponectin.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 22, 2018
    Assignee: UNIVERSITY OF TARTU
    Inventors: Tiiu Kullisaar, Mihkel Zilmer, Imbi Smidt, Kersti Zilmer, Marika Mikelsaar, Pirje Hütt
  • Patent number: 9961304
    Abstract: Disclosed herein is an ultrasonic image processing method and apparatus. The ultrasonic image processing method includes acquiring volume data by radiating ultrasonic waves to an area around the uterus, extracting at least one object candidate group based on the acquired volume data, and displaying the at least one extracted object candidate group on a screen. The ultrasonic image processing apparatus includes a data acquisition unit acquiring volume data of an area around the uterus using ultrasonic waves, a data processing unit extracting at least one object candidate group based on the acquired volume data, and a display unit displaying the at least one extracted object candidate group on a screen.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: May 1, 2018
    Assignee: SAMSUNG MEDISON CO., LTD.
    Inventors: Sung Yoon Kim, Jun Sang Yoo
  • Patent number: 9943552
    Abstract: Methods for treating Alzheimer's disease, or the symptoms of Alzheimer's disease, are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells, such as cell derivatives. Some embodiments are to methods for treatment comprising hUTC. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 17, 2018
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Anthony J. Kihm, Anna Gosiewska
  • Patent number: 9944952
    Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: April 17, 2018
    Assignee: Universität Zürich
    Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
  • Patent number: 9937211
    Abstract: A first aspect of the invention relates to the bacterial species Roseburia hominis for use in: regulating the immune system of a subject treating an immune disorder; treating an intestinal disorder; improving intestinal microbiota; regulating the innate immune system of a subject; regulating the adaptive immune system of a subject; regulating appetite in a subject; promoting Tregs and immune tolerance; promoting gut health in a subject; and/or maintaining immune homeostasis in a subject. Further aspects of the invention relate to compositions comprising Roseburia hominis.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 10, 2018
    Assignee: 4D Pharma Research Limited
    Inventors: Denise Kelly, Imke Mulder
  • Patent number: 9937206
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: April 10, 2018
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • Patent number: 9937249
    Abstract: A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: April 10, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Jaeyun Kim, Weiwei Aileen Li, David J. Mooney
  • Patent number: 9925221
    Abstract: Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 27, 2018
    Assignee: Celularity, Inc.
    Inventors: Robert J. Hariri, Jodi P. Gurney
  • Patent number: 9895400
    Abstract: A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: February 20, 2018
    Assignee: Genmont Biotech Inc.
    Inventors: Yi-Hsing Chen, Ya-Hui Chen, Tzu-Chi Lou, Ting-Yun Shen
  • Patent number: 9894903
    Abstract: The invention relates to a process for combating the proliferation of the Naegleria genus and in particular of the species Naegleria fowleri, with the exception of the treatment methods applied to the human or animal body, characterized in that it uses protozoa of the species Willaertia magna, and also a disinfecting agent containing such protozoa.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: February 20, 2018
    Assignee: AMOEBA
    Inventors: Fabrice Plasson, Mouh Oulhadj Mameri
  • Patent number: 9861669
    Abstract: Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: January 9, 2018
    Assignees: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Zahari Raykov, Svitlana Grekova, Irina Kiprijanova, Karsten Geletneky, Ute Koch, Marc Aprahamian
  • Patent number: 9834788
    Abstract: The present invention relates to gene therapy for treatment or prevention of choroideremia.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: December 5, 2017
    Assignee: Oxford University Innovation Limited
    Inventors: Robert Maclaren, Miguel Seabra, Matthew John During
  • Patent number: 9827295
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 28, 2017
    Assignees: Regents of the University of Minnesota, REGENXBIO Inc.
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • Patent number: 9828587
    Abstract: The invention provides an isolated chimeric virus comprising bocavirus capsid protein, e.g., an isolated chimeric virus comprising human bocavirus capsid protein, and a recombinant adeno-associated viral (AAV) genome, an isolated recombinant bocavirus (rBoV) comprising human bocavirus capsid protein and a recombinant Boy genome, and uses therefor, for example, in gene therapy for diseases in a mammal including diseases with aberrant expression of an endogenous gene product.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: November 28, 2017
    Assignee: University of Iowa Research Foundation
    Inventors: Ziying Yan, John F. Engelhardt, Jianming Qiu
  • Patent number: 9808536
    Abstract: The present invention discloses a hypericin albumin nanoparticle-Escherichia coli serum antibody complex, which is obtained through adding mixed hypericin albumin nanoparticles and rabbit anti-Escherichia colis into ethanediol, irradiating them with carbon ion, setting them at a low temperature for 2 hours after irradiation, centrifuging them at a low temperature, and freezing and drying the precipitates. Its preparation method and application are also provided.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 7, 2017
    Assignee: LANZHOU INSTITUTE OF HUSBANDRY AND PHARMACEUTICAL SCIENCES OF CAAS
    Inventors: Jianping Liang, Wenzhu Guo, Baocheng Hao, Lei Tao, Yu Liu, Xuehong Wang, Ruofeng Shang, Zhiting Guo, Fengwu Zhao, Zhen Yang, Hong Chen, Zhong Jia
  • Patent number: 9809800
    Abstract: A method for stably and easily producing a parvovirus having a high infectivity titer is provided. The problem is solved by a method for producing a parvovirus having an infectivity titer as high as 108 TCID50/mL or more in a culture supernatant, comprising the steps of inoculating a seed virus of the parvovirus into a culture substrate comprising host cells having a cell density of 1/500 to 1/20 of the cell density of the host cells confluently grown and a medium at a multiplicity of infection of 0.0001 to 0.1, culturing for a period of 5 to 11 times the doubling time of the host cells, and recovering a culture supernatant.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: November 7, 2017
    Assignee: ASAHI KASEI MEDICAL CO., LTD.
    Inventor: Koichiro Yanagida
  • Patent number: 9801326
    Abstract: Embodiments of a technique are provided for removing dust from treated seeds. The method includes applying a treatment to a number of seeds at a seed treatment station and at least partially drying the seeds at the treatment station. The partially dried seeds may then be conveyed through a conveying station from the treatment station to an output area. Air may be directed through an inlet of the conveying station, where the directed air is configured to remove non-seed particles from the seeds. Furthermore, air may be filtered through an outlet of the conveying station to capture the removed non-seed particles using a filtering system. In some cases, an initial temperature of the air may be controlled to optimize the dust removal process, such as by heating and/or chilling the air.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 31, 2017
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Michael K. Dammen, Timothy P. Meyer
  • Patent number: 9775863
    Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Etienne Sokal, Mustapha Najimi
  • Patent number: 9750774
    Abstract: The present invention concerns the probiotic strain Bacillus subtilis CU1 filed with the French Collection Nationale de Culture des Microorganismes (National Collection of Microorganism Cultures) under number I-2745, cells obtained by culturing said strain and a composition comprising cells obtained by culturing said strain, for the use thereof in the treatment and/or prevention of chronic inflammatory diseases, and in particular chronic inflammatory rheumatism.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: September 5, 2017
    Assignees: LESAFFRE ET COMPAGNIE, ECOLE NATIONALE SUPERIEURE DES SCIENCES AGRONOMIQUES DE BORDEAUX AQUITAINE (BORDE AUX SCIENCES AGRO)
    Inventors: Patrick Taillade, Maria Urdaci
  • Patent number: 9744226
    Abstract: The present invention provides attenuated M. haemolitica strains that elicit an immune response in animal against M. haemolitica, compositions comprising said strains, methods of vaccination against M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: August 29, 2017
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Biotechnology Research and Development Corporation
    Inventors: Robert E. Briggs, Fred M. Tatum